MDGL250516P280000
- 4.20
- -2.70-39.13%
Madrigal Pharmaceuticals Newsroom
Uncovering Potential: Madrigal Pharmaceuticals's Earnings Preview
Cantor Fitzgerald Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating
Earnings Preview: MDGL to Report Financial Results Pre-market on May 01
12 Health Care Stocks Moving In Friday's After-Market Session
Evercore Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $392
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Pfizer (PFE) and Madrigal Pharmaceuticals (MDGL)
JMP Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $443
Express News | JMP Securities Reiterates Market Outperform on Madrigal Pharmaceuticals, Maintains $443 Price Target
Madrigal Pharmaceuticals Analyst Ratings
TD Cowen Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Insiders Sold US$4.4m Of Shares Suggesting Hesitancy
Jefferies Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $398
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025
Express News | Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.d. to Become Senior Scientific and Medical Advisor; David Soergel, M.d., Appointed Chief Medical Officer
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer
SA Asks: Which Cardiology Drug Companies Could Be Takeout Candidates?
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL): Are Analysts Optimistic?
Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires
Madrigal Pharmaceuticals(MDGL.US) Director Sells US$5.08 Million in Common Stock